Emerging Strategies for the Management of Atherogenic Dyslipidaemia.
作者信息
Agarwala Anandita, Shapiro Michael D
机构信息
Division of Cardiology, Washington University School of Medicine, St Louis, MO, US.
Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, US.
出版信息
Eur Cardiol. 2020 Feb 26;15:1-3. doi: 10.15420/ecr.2019.16. eCollection 2020 Feb.
Abstract
摘要
相似文献
1
Emerging Strategies for the Management of Atherogenic Dyslipidaemia.动脉粥样硬化性血脂异常管理的新策略
Eur Cardiol. 2020 Feb 26;15:1-3. doi: 10.15420/ecr.2019.16. eCollection 2020 Feb.
2
[The role of atherogenic dyslipidaemia in clinical practice guidelines].[致动脉粥样硬化性血脂异常在临床实践指南中的作用]
Clin Investig Arterioscler. 2016 Mar-Apr;28(2):65-70. doi: 10.1016/j.arteri.2015.12.004. Epub 2016 Mar 2.
3
[Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis].类风湿关节炎患者的血脂异常与动脉粥样硬化风险
Clin Investig Arterioscler. 2016 May-Jun;28(3):123-31. doi: 10.1016/j.arteri.2016.02.002. Epub 2016 Mar 26.
4
ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients.ENHO、RXRA和LXRA基因多态性与血液透析患者的血脂异常、相关合并症及生存率
BMC Med Genet. 2018 Nov 9;19(1):194. doi: 10.1186/s12881-018-0708-4.
5
Relationship between Atherogenic Dyslipidaemia and Lipid Triad and Scales That Assess Insulin Resistance.致动脉粥样硬化性血脂异常与脂质三联症和评估胰岛素抵抗的量表之间的关系。
Nutrients. 2023 Apr 27;15(9):2105. doi: 10.3390/nu15092105.
6
Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.2019 年欧洲血脂异常管理指南中的甘油三酯、高密度脂蛋白胆固醇和致动脉粥样硬化性血脂异常。
Clin Investig Arterioscler. 2020 Sep-Oct;32(5):209-218. doi: 10.1016/j.arteri.2019.12.003. Epub 2020 Feb 6.
7
8
[Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus].[系统性红斑狼疮患者的血脂异常与动脉粥样硬化风险]
Med Clin (Barc). 2016 Jul 15;147(2):63-6. doi: 10.1016/j.medcli.2016.03.030. Epub 2016 May 16.
9
Risk factors, comorbiditiEs and Atherogenic dysLipidaemia in Indian YOUNG patients with dyslipidaemia attending hospital/clinic: REAL YOUNG (dyslipidaemia) study.印度血脂异常的年轻住院/门诊患者的危险因素、合并症及致动脉粥样硬化性血脂异常：REAL YOUNG（血脂异常）研究
J Family Med Prim Care. 2020 Aug 25;9(8):4156-4164. doi: 10.4103/jfmpc.jfmpc_546_20. eCollection 2020 Aug.
10
Diabetic dyslipidaemia.糖尿病血脂异常
Pract Lab Med. 2021 Jul 18;26:e00248. doi: 10.1016/j.plabm.2021.e00248. eCollection 2021 Aug.
引用本文的文献
1
Remnant cholesterol is associated with cardiovascular mortality.残余胆固醇与心血管疾病死亡率相关。
Front Cardiovasc Med. 2022 Sep 20;9:984711. doi: 10.3389/fcvm.2022.984711. eCollection 2022.
2
Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project.真实世界临床实践中血脂异常的管理：VIPFARMA ISCP项目的基本原理与设计
Eur Cardiol. 2021 Apr 27;16:e16. doi: 10.15420/ecr.2020.42. eCollection 2021 Feb.
本文引用的文献
1
The Use of Risk Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-society Cholesterol Guidelines.利用风险增强因素实现动脉粥样硬化性心血管疾病（ASCVD）风险评估的个性化：2018年美国心脏协会/美国心脏病学会多学会胆固醇指南的证据与建议
Curr Cardiovasc Risk Rep. 2019;13(7). doi: 10.1007/s12170-019-0616-y. Epub 2019 May 23.
2
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease.动脉粥样硬化性血脂异常与心血管疾病的新视角
Eur Cardiol. 2020 Feb 26;15:1-9. doi: 10.15420/ecr.2019.06. eCollection 2020 Feb.
3
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南：通过血脂修饰降低心血管风险
Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31.
4
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.贝特帕酸联合依折麦布固定剂量复方制剂在最大耐受他汀治疗的高胆固醇血症和高 CVD 风险患者中的应用。
Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29.
5
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.N-乙酰半乳糖胺修饰的抗载脂蛋白 C3mRNA 反义药物，用于降低甘油三酯和致动脉粥样硬化脂蛋白水平。
Eur Heart J. 2019 Sep 1;40(33):2785-2796. doi: 10.1093/eurheartj/ehz209.
6
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.单克隆抗体抑制血管生成素样蛋白 3 可降低高甘油三酯血症中的甘油三酯。
Circulation. 2019 Aug 6;140(6):470-486. doi: 10.1161/CIRCULATIONAHA.118.039107. Epub 2019 Jun 27.
7
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.脂蛋白(a)在临床实践中的应用：是时候使用这个标志物了。美国国家脂质协会的科学声明。
J Clin Lipidol. 2019 May-Jun;13(3):374-392. doi: 10.1016/j.jacl.2019.04.010. Epub 2019 May 17.
8
Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.依折麦布与烟酸联合或不联合治疗对脂蛋白(a)浓度的影响。
J Clin Lipidol. 2019 Jul-Aug;13(4):580-585. doi: 10.1016/j.jacl.2019.04.008. Epub 2019 Apr 26.
9
Antisense Oligonucleotides Targeting Lipoprotein(a).靶向脂蛋白(a)的反义寡核苷酸。
Curr Atheroscler Rep. 2019 May 20;21(8):30. doi: 10.1007/s11883-019-0792-8.
10
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.贝匹地酸治疗高胆固醇血症及他汀类药物不耐受患者的疗效和安全性。
J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662.
Zotero 插件